Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) released its Monthly Return for Equity Issuer for the period ended 30 September 2026, indicating no changes in either authorised or issued share capital during the month.

Authorised and Issued Capital • Authorised share capital remains at 3.71 billion shares, split between 919.07 million H-shares and 2.79 billion A-shares, each with a par value of RMB 1.00. • Issued shares mirror the authorised amounts: 919.07 million H-shares and 2.79 billion A-shares, totalling 3.71 billion issued shares. • The company holds zero treasury shares, and no share repurchases, cancellations, or new issues occurred in September.

Capital-Raising Instruments • No movements were recorded under share option schemes, warrants, convertible securities, or other equity-linked instruments. • There were no Hong Kong Depositary Receipt activities for the month.

Regulatory Compliance • SH PHARMA confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 5% for its H-share class. • All regulatory confirmations under Main Board Rule 13.25C were affirmed, covering receipt of funds, listing qualifications, and documentation requirements.

Outlook The unchanged share structure underscores SH PHARMA’s stable capital position as it enters the final quarter of 2026. With public-float standards met and no dilutive instruments outstanding, the company maintains a straightforward equity profile ahead of any future capital market activities.